{"id":"NCT00089661","sponsor":"Amgen","briefTitle":"AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer","officialTitle":"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-10-01","primaryCompletion":"2007-05-11","completion":"2009-05-27","firstPosted":"2004-08-11","resultsPosted":"2010-01-26","lastUpdate":"2018-10-17"},"enrollment":252,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Breast Cancer","Low Bone Mineral Density","Osteopenia"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"AMG 162 / Denosumab","otherNames":[]}],"arms":[{"label":"AMG 162 / Denosumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.","primaryOutcome":{"measure":"Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12","timeFrame":"12 months","effectByArm":[{"arm":"Denosumab 60 mg Q6M","deltaMin":4.8,"sd":null},{"arm":"Placebo","deltaMin":-0.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["19308727","18725648","38979716"],"seeAlso":["http://www.amgentrials.com","http://download.veritasmedicine.com/REGFILES/amgen/Amgen_results_disclaimer.pdf"]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":120},"commonTop":["Arthralgia","Fatigue","Back pain","Pain in extremity","Constipation"]}}